유럽 ​​위암 진단 시장 – 2030년까지의 산업 동향 및 예측

보고서 사용자 지정 보고서 사용자 지정 지금 구매 지금 구매 무료 샘플 보고서 무료 샘플 보고서
집 Healthcare IT Europe Gastric Cancer Diagnostics Market
TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

유럽 ​​위암 진단 시장 – 2030년까지의 산업 동향 및 예측

  • Healthcare IT
  • Published Report
  • Mar 2023
  • Europe
  • 350 Pages
  • 테이블 수: 250
  • 그림 수: 56
지금 구매 지금 구매

Europe Gastric Cancer Diagnostics Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
 2024 –2030
Diagram 시장 규모(기준 연도)
 백만 달러
요구
Diagram 시장 규모(예측 연도)
 미국 달러 428.98
Diagram 연평균 성장률
 %
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
잠금 해제 요청

>유럽 ​​위암 진단 시장, 제품 유형(기구, 시약 및 소모품, 서비스), 진단 유형(위암(사전) 검진 검사/신체 검사, 확인 검사), 연령대(성인, 소아 및 노인), 유형(장 또는 확산성 선암, 카르시노이드 종양, 위장관 기질 종양 (GIST), 위 림프종 및 기타), 병기(0기, 1기, 2기, 3기), 성별(남성 및 여성), 샘플 유형(혈액, 조직, 소변 및 대변), 최종 사용자(진단 실험실, 병원, 암 연구소, 종양 전문 클리닉 및 기타), 유통 채널(직접 입찰 및 소매 판매) 산업 동향 및 2030년까지의 예측.

유럽 ​​위암 진단 시장

유럽 ​​위암 진단 시장 분석 및 통찰력

유럽 ​​노령 인구의 증가는 위암 진단 산업의 성장을 주도하고 있습니다. 위장관 종양과 림프종의 유병률도 위암 진단에 대한 수요를 촉진했습니다. 주요 시장 제약은 개발도상국도 혜택을 받을 수 있도록 암 진단 검사와 관련된 높은 가격을 낮춰야 한다는 필요성입니다.

유럽 ​​위암 진단 시장

유럽 ​​위암 진단 시장

수많은 시장 참여자들이 혁신을 통해 위암 진단 제품을 제공하고 있으며, 이는 유럽 위암 진단 시장 성장의 길을 열어주고 있습니다.

Data Bridge Market Research는 유럽 위암 진단 시장이 2030년까지 4억 2,898만 달러 규모에 도달할 것으로 예상하며, 예측 기간 동안 CAGR은 8.1%라고 분석했습니다. 시약 및 소모품은 키트 및 시약에 대한 수요가 증가하고 의료비 지출이 증가함에 따라 스마트 의료 기기에 대한 수요가 가속화되어 시장에서 가장 큰 제품 유형 세그먼트를 차지합니다.

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 연도

2021 (2015-2020으로 사용자 정의 가능)

양적 단위

매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시됨

다루는 세그먼트

제품 유형별(기구, 시약 및 소모품, 서비스), 진단 유형별(확증 검사, 위암 검진 검사/신체 검사), 연령대별(성인, 소아 및 노인), 질병 유형별(장 또는 확산성 선암, 카르시노이드 종양, 위장관 기질 종양(GIST), 위 림프종 및 기타), 병기별(0기, 1기, 2기, 3기), 성별별(남성 및 여성), 샘플 유형별(혈액, 조직, 소변 및 대변), 최종 사용자별(진단 실험실, 병원, 암 연구소, 종양학 전문 병원 및 기타), 유통 채널별(직접 입찰 및 소매 판매)

적용 국가

독일, 영국, 프랑스, ​​이탈리아, 스페인, 네덜란드, 러시아, 스위스, 터키, 벨기에, 기타 유럽

시장 참여자 포함

BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, FOUNDATION MEDICINE, INC., DiaSorin S.p.A, and Paragon Genomics, Inc., QIAGEN among others

Market Definition

Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below the ribs in the upper part of the abdomen. The stomach takes in and holds the food we eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for the diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scans, and ultrasound among others.

Cancer is caused by uncontrolled, abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer.

Europe Gastric Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

 Drivers

  • Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma

According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.

It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.

Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the Europe gastric cancer diagnostics market.

  • Rise in alcohol consumption and surge in smoking

Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone and so represents a severe public health issue that warrants further investigation.

A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.

Thus, the rise in alcohol consumption and surge in smoking is expected to drive the Europe gastric cancer market growth.

Opportunity

  • Rise in adoption of automated systems

Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress.

Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for instance, is a new field focused on multidimensional data processing. It can also benefit from AI advancements.

Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.

Restraint/Challenge

  • Lack of sufficient financial support from health insurance policies

To achieve their objectives, health systems require financial resources. Human resources, hospital care, and medications are the most expensive aspects of most healthcare systems. In most tropical countries, health care is funded through a combination of government, private (mainly out-of-pocket) spending, and international help.

Healthcare finance remains a key concern for low- and lower-middle-income countries. Many upper-middle-income countries in Latin America, Africa, and Asia have been able to establish health finance arrangements that cover large segments of their populations. These measures enable access to health care while also protecting individuals from catastrophic debt incurred as a result of that access. Finance, on the other hand, is a major obstacle to health care delivery in low-income countries (the bulk of which are in Sub-Saharan Africa).

Thus, the lack of sufficient financial support from health insurance policies acts as a restraint to market's growth.

Recent Developments

  • In October 2022, General Electric Company collaborated with several research institutes such as the University of Cambridge Hospitals, Sophia Genetics, and earlier with Optellum to use imaging data in collaboration with Artificial intelligence. This will help to reduce the diagnosing time of several cancers and help to provide personalized care to patients. This has helped the company to widen its horizons in cancer diagnostics
  • In March 2020, Thermo Fisher Scientific Inc. announced that it would be acquiring QIAGEN, a Netherland-based molecular diagnostics and healthcare company. This acquisition by the company will increase its product portfolio in the market, leading to increased revenue in future

Europe Gastric Cancer Diagnostics Market Scope

The Europe gastric cancer diagnostics market is segmented into nine notable segments based on product type, diagnostic type, age group, disease type, stage, gender, sample, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

PRODUCT TYPE

  • Instruments
  • Reagents & Consumables
  • Services

On the basis of product type, the market is segmented into instruments, reagents & consumables, and services.

DIAGNOSTIC TYPE

  • Confirmatory Test
  • Gastric Cancer Screening Tests/Physical Exam

On the basis of diagnostics type, the market is segmented into gastric cancer screening tests/physical exam and confirmatory tests.

AGE GROUP

  • Adult
  • Pediatric
  • Geriatrics

On the basis of age group, the market is segmented into adult, pediatric, and geriatrics.

TYPE

  • Intestinal Or Diffuse Adenocarcinoma
  • Carcinoid Tumor
  • Gastrointestinal Stromal Tumor (GIST)
  • Gastric Lymphoma
  • Others

On the basis of type, the market is segmented into intestinal or diffuse adenocarcinoma, carcinoid tumor, gastrointestinal stromal tumor (GIST), gastric lymphoma, and others.

STAGE

  • Stage 0
  • Stage I
  • Stage II
  • Stage III

On the basis of stage, the market is segmented into stage 0, stage I, stage II, and stage III.

GENDER

  • Male
  • Female

On the basis of gender, the market is segmented into male and female.

SAMPLE TYPE

  • Blood
  • Tissue
  • Urine
  • Stool

On the basis of sample type, the market is segmented into blood, tissue, urine, and stool.

END USER

  • Diagnostic Laboratories
  • Hospitals
  • Cancer Research Institutes
  • Oncology Specialty Clinics
  • Others

On the basis of end users, the market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others.

DISTRIBUTION CHANNEL

  • Direct Tenders
  • Retail Sales

On the basis of distribution channel, the market is segmented into direct tender and retail sales.

Europe Gastric Cancer Diagnostics Market Regional Analysis/Insights

The Europe gastric cancer diagnostics market is segmented into nine notable segments based on product type, diagnostic type, age group, disease type, stage, gender, sample, end user, and distribution channel. 

이 시장 보고서에서 다루는 국가는 독일, 프랑스, ​​영국, 러시아, 이탈리아, 스페인, 벨기에, 네덜란드, 터키, 스위스 및 기타 유럽 국가입니다.

림프종과 선암의 유병률이 증가함에 따라 독일이 유럽 위암 진단 시장을 장악할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 유럽 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 위암 진단 시장 점유율 분석

유럽 ​​위암 진단 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭과 범위, 응용 프로그램 우세, 제품 유형 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 위암 진단 시장에 대한 회사의 초점과만 관련이 있습니다.

이 시장에서 활동하는 주요 기업으로는 BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Fujirebio(HU 그룹 계열사), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, FOUNDATION MEDICINE, INC., DiaSorin SpA, Paragon Genomics, Inc., QIAGEN 등이 있습니다.

 

SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

Sample Image Click on image to enlarge
  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of EUROPE gastric cancer diagnostics market
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. packaging LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. vendor share analysis
    11. MARKET END USER COVERAGE GRID
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. PREMIUM INSIGHTS
    1. ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML) IN GASTRIC CANCER DIAGNOSTICS
    2. products (brands) Detailed information
  5. REGULATIONS OF EUROPE GASTRIC CANCER DIAGNOSTICS MARKET
  6. Epidemiology
  7. market overview
    1. DRIVERS
      1. INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA
      2. RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING
      3. INCREASE IN THE GERIATRIC POPULATION
      4. STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
      5. RECENT ADVANCES IN GASTRIC CANCER DIAGNOSTICS
    2. RESTRAINTS
      1. HIGH COST OF TESTING
      2. LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES
    3. OPPORTUNITIES
      1. RISING HEALTHCARE SPENDING
      2. ADOPTION OF AUTOMATED SYSTEMS
      3. INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS
    4. CHALLENGES
      1. STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES
      2. LIMITATIONS OF RADIATION TESTS
  8. IMPACT OF COVID-19 ON EUROPE GASTRIC CANCER DIAGNOSTICS MARKET
    1. IMPACT ON PRICE
    2. IMPACT ON DEMAND
    3. IMPACT ON SUPPLY CHAIN
    4. KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
    5. CONCLUSION
  9. Europe gastric cancer diagnostics market, By product type
    1. overview
    2. Reagents & Consumables
      1. Kits
        1. DNA POLYMERASE KITS
        2. PCR KITS
        3. NUCLEIC ACID ISOLATION KITS
        4. OTHERS
      2. Reagents
        1. ASSAYS
        2. BUFFERS
        3. PRIMERS
        4. OTHERS
    3. instruments
    4. services
  10. Europe gastric cancer diagnostics market, By diagnostic type
    1. overview
    2. confirmatory test
      1. imaging tests
        1. PET SCAN/CT SCAN
        2. CT SCAN
        3. ULTRASOUND
        4. MRI
        5. X-RAY
      2. biomarker
        1. DNA BIOMARKER
        2. RNA BIOMARKER
        3. PROTEIN BIOMARKER
      3. biopsy
    3. gastric cancer screening tests/physical exam
  11. Europe gastric cancer diagnostics market, By age group
    1. overview
    2. geriatrics
    3. adult
    4. pediatric
  12. Europe gastric cancer diagnostics market, By disease type
    1. overview
    2. intestinal or diffuse adenocarcinoma
    3. carcinoid tumor
    4. gastrointestinal stromal tumor
    5. gastric lymphoma
    6. others
  13. Europe gastric cancer diagnostics market, By stage
    1. overview
    2. stage i
      1. stage iA
      2. stage iB
    3. stage iI
      1. stage IiA
      2. stage IiB
    4. stage iII
      1. stage IiIA
      2. stage IiIB
      3. stage IiIC
    5. stage 0
  14. Europe gastric cancer diagnostics market, By GENDER
    1. overview
    2. male
    3. female
  15. Europe gastric cancer diagnostics market, By sample type
    1. overview
    2. stool
    3. tissue
    4. blood
    5. urine
  16. Europe gastric cancer diagnostics market, By end user
    1. overview
    2. hospitals
    3. diagnostic laboratories
    4. cancer research institutes
    5. oncology specialty clinics
    6. others
  17. Europe gastric cancer diagnostics market, By distribution channel
    1. overview
    2. direct tenders
    3. Retail Sales
  18. EUROPE gastric cancer diagnostics MARKET, BY REGION
    1. EUROPE
      1. Germany
      2. France
      3. U.K.
      4. Russia
      5. Italy
      6. Spain
      7. Belgium
      8. Netherlands
      9. Turkey
      10. Switzerland
      11. Rest of Europe
  19. EUROPE Gastric Cancer diagnostics Market: COMPANY landscape
    1. company share analysis: Europe
  20. SWOT
  21. Company profile
    1. F. Hoffmann-La Roche Ltd
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. COMPANY SHARE ANALYSIS
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENT
    2. GENERAL ELECTRIC COMPANY
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. COMPANY SHARE ANALYSIS
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENT
    3. BIOMÉRIEUX SA
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. COMPANY SHARE ANALYSIS
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENT
    4. Myriad Genetics, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. COMPANY SHARE ANALYSIS
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENT
    5. abbott
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. COMPANY SHARE ANALYSIS
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENT
    6. ACON Laboratories, Inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    7. ADVACARE PHARMA
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    8. AGILENT TECHNOLOGIES, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    9. BIOCEPT, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    10. Biohit Oyj
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    11. DiaSorin S.p.A
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    12. Endofotonics Pte Ltd
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    13. foundation medicine, inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    14. fujirebio (an h.u. group company)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    15. MiRXES
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    16. Paragon Genomics, Inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    17. qiagen
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    18. teco diagnostics
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    19. Thermo Fisher Scientific Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    20. vela diagnostics
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
  22. questionnaire
  23. related reports

표 목록

TABLE 1 Europe gastric cancer diagnostics market, By product type, 2019-2028 (USD million)

TABLE 2 Europe reagents & consumables in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 3 Europe Reagent and consumables IN gastric cancer diagnostics market, By product type, 2019-2028 (USD million)

TABLE 4 Europe kits IN gastric cancer diagnostics market, By product type, 2019-2028 (USD million)

TABLE 5 Europe reagents IN gastric cancer diagnostics market, By product type, 2019-2028 (USD million)

TABLE 6 Europe instruments in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 7 Europe services in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 8 Europe gastric cancer diagnostics market, By diagnostic type, 2019-2028 (USD million)

TABLE 9 Europe confirmatory test in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 10 Europe confirmatory test in Gastric cancer diagnostics Market, By diagnostic type, 2019-2028 (USD Million)

TABLE 11 Europe imaging tests in Gastric cancer diagnostics Market, By diagnostic type, 2019-2028 (USD Million)

TABLE 12 Europe biomarker in Gastric cancer diagnostics Market, By diagnostic type, 2019-2028 (USD Million)

TABLE 13 Europe gastric cancer screening tests/physical exam in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 14 Europe gastric cancer diagnostics market, By age group, 2019-2028 (USD million)

TABLE 15 Europe geriatrics in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 16 Europe adult in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 17 Europe pediatric in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 18 Europe gastric cancer diagnostics market, By disease type, 2019-2028 (USD million)

TABLE 19 Europe intestinal or diffuse ADENOCARCINOMA in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 20 Europe carcinoid tumor in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 21 Europe gastrointestinal stromal tumor in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 22 Europe gastric lymphoma in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 23 Europe others in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 24 Europe gastric cancer diagnostics market, By stage, 2019-2028 (USD million)

TABLE 25 Europe stage i in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 26 Europe stage i in Gastric cancer diagnostics Market, By stage, 2019-2028 (USD Million)

TABLE 27 Europe stage iI in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 28 Europe stage iI in Gastric cancer diagnostics Market, By stage, 2019-2028 (USD Million)

TABLE 29 Europe stage iII in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 30 Europe stage iIi in Gastric cancer diagnostics Market, By stage, 2019-2028 (USD Million)

TABLE 31 Europe stage 0 in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 32 Europe gastric cancer diagnostics market, By gender, 2019-2028 (USD million)

TABLE 33 Europe male in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 34 Europe female in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 35 Europe gastric cancer diagnostics market, By sample type, 2019-2028 (USD million)

TABLE 36 Europe stool in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 37 Europe tissue in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 38 Europe blood in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 39 Europe urine in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 40 Europe gastric cancer diagnostics market, By end user, 2019-2028 (USD million)

TABLE 41 Europe HOSPITALS in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 42 Europe diagnostic laboratories in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 43 Europe cancer research institutes in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 44 Europe oncology specialty clinics in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 45 Europe others in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 46 Europe gastric cancer diagnostics market, By distribution channel, 2019-2028 (USD million)

TABLE 47 Europe direct tenders in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 48 Europe Retail Sales in Gastric cancer diagnostics Market, By Region, 2019-2028 (USD Million)

TABLE 49 EUROPE Gastric Cancer Diagnostics Market, By COUNTRY, 2019-2028 (USD Million)

TABLE 50 Europe Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 51 Europe Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 52 Europe Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 53 Europe Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 54 Europe Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 55 Europe Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 56 Europe Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 57 Europe Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 58 Europe Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 59 Europe Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 60 Europe Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 61 Europe Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 62 Europe Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 63 Europe Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 64 Europe Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 65 Europe Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 66 Europe Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 67 Europe Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 68 Germany Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 69 Germany Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 70 Germany Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 71 Germany Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 72 Germany Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 73 Germany Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 74 Germany Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 75 Germany Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 76 Germany Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 77 Germany Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 78 Germany Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 79 Germany Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 80 Germany Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 81 Germany Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 82 Germany Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 83 Germany Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 84 Germany Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 85 Germany Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 86 France Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 87 France Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 88 France Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 89 France Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 90 France Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 91 France Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 92 France Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 93 France Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 94 France Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 95 France Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 96 France Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 97 France Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 98 France Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 99 France Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 100 France Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 101 France Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 102 France Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 103 France Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 104 U.K. Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 105 U.K. Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 106 U.K. Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 107 U.K. Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 108 U.K. Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 109 U.K. Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 110 U.K. Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 111 U.K. Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 112 U.K. Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 113 U.K. Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 114 U.K. Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 115 U.K. Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 116 U.K. Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 117 U.K. Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 118 U.K. Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 119 U.K. Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 120 U.K. Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 121 U.K. Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 122 Russia Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 123 Russia Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 124 Russia Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 125 Russia Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 126 Russia Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 127 Russia Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 128 Russia Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 129 Russia Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 130 Russia Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 131 Russia Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 132 Russia Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 133 Russia Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 134 Russia Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 135 Russia Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 136 Russia Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 137 Russia Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 138 Russia Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 139 Russia Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 140 Italy Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 141 Italy Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 142 Italy Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 143 Italy Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 144 Italy Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 145 Italy Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 146 Italy Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 147 Italy Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 148 Italy Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 149 Italy Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 150 Italy Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 151 Italy Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 152 Italy Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 153 Italy Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 154 Italy Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 155 Italy Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 156 Italy Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 157 Italy Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 158 Spain Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 159 Spain Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 160 Spain Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 161 Spain Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 162 Spain Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 163 Spain Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 164 Spain Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 165 Spain Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 166 Spain Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 167 Spain Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 168 Spain Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 169 Spain Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 170 Spain Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 171 Spain Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 172 Spain Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 173 Spain Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 174 Spain Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 175 Spain Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 176 Belgium Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 177 Belgium Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 178 Belgium Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 179 Belgium Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 180 Belgium Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 181 Belgium Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 182 Belgium Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 183 Belgium Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 184 Belgium Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 185 Belgium Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 186 Belgium Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 187 Belgium Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 188 Belgium Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 189 Belgium Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 190 Belgium Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 191 Belgium Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 192 Belgium Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 193 Belgium Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 194 Netherlands Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 195 Netherlands Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 196 Netherlands Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 197 Netherlands Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 198 Netherlands Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 199 Netherlands Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 200 Netherlands Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 201 Netherlands Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 202 Netherlands Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 203 Netherlands Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 204 Netherlands Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 205 Netherlands Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 206 Netherlands Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 207 Netherlands Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 208 Netherlands Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 209 Netherlands Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 210 Netherlands Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 211 Netherlands Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 212 Turkey Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 213 Turkey Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 214 Turkey Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 215 Turkey Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 216 Turkey Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 217 Turkey Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 218 Turkey Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 219 Turkey Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 220 Turkey Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 221 Turkey Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 222 Turkey Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 223 Turkey Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 224 Turkey Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 225 Turkey Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 226 Turkey Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 227 Turkey Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 228 Turkey Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 229 Turkey Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 230 Switzerland Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 231 Switzerland Reagents & Consumables in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 232 Switzerland Kits in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 233 Switzerland Reagents in Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 234 Switzerland Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 235 Switzerland Confirmatory tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 236 Switzerland Imaging Tests in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 237 Switzerland Biomarker in Gastric Cancer Diagnostics Market, By Diagnostic Type, 2019-2028 (USD Million)

TABLE 238 Switzerland Gastric Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 239 Switzerland Gastric Cancer Diagnostics Market, By Disease Type, 2019-2028 (USD Million)

TABLE 240 Switzerland Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 241 Switzerland Stage I in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 242 Switzerland Stage II in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 243 Switzerland Stage III in Gastric Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 244 Switzerland Gastric Cancer Diagnostics Market, By Gender, 2019-2028 (USD Million)

TABLE 245 Switzerland Gastric Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 246 Switzerland Gastric Cancer Diagnostics Market, By End User, 2019-2028 (USD Million)

TABLE 247 Switzerland Gastric Cancer Diagnostics Market, By Distribution CHannel, 2019-2028 (USD Million)

TABLE 248 Rest of Europe Gastric Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

그림 목록

FIGURE 1 Europe GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 Europe Gastric cancer diagnostics market: DROC ANALYSIS

FIGURE 4 Europe Gastric cancer diagnostics market: Europe VS. REGIONAL MARKET ANALYSIS

FIGURE 5 Europe Gastric cancer diagnostics market: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE Gastric cancer diagnostics market: MULTIVARIATE MODELLING

FIGURE 7 EUROPE Gastric cancer diagnostics market: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE gastric cancer diagnostics market: MARKET END USER COVERAGE GRID

FIGURE 11 Europe Gastric cancer diagnostics market: SEGMENTATION

FIGURE 12 Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma is expected to DRIVe THE Europe Gastric cancer diagnostics market IN THE FORECAST PERIOD OF 2021 to 2028

FIGURE 13 reagents and consumables SEGMENT is expected to account for the largest share of the Europe GASTRIC CANCER DIAGNOSTICS MARKET in 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGEs OF Europe Gastric cancer diagnostics Market

FIGURE 15 Europe gastric cancer diagnostics market: By product type, 2020

FIGURE 16 Europe gastric cancer diagnostics market: By product type, 2021-2028 (USD Million)

FIGURE 17 Europe gastric cancer diagnostics market: By product type, CAGR (2021-2028)

FIGURE 18 Europe gastric cancer diagnostics market: By product type, LIFELINE CURVE

FIGURE 19 Europe gastric cancer diagnostics market: By diagnostic type, 2020

FIGURE 20 Europe gastric cancer diagnostics market: By diagnostic type, 2021-2028 (USD Million)

FIGURE 21 Europe gastric cancer diagnostics market: By diagnostic type, CAGR (2021-2028)

FIGURE 22 Europe gastric cancer diagnostics market: By diagnostic type, LIFELINE CURVE

FIGURE 23 Europe gastric cancer diagnostics market: By age group, 2020

FIGURE 24 Europe gastric cancer diagnostics market: By age group, 2021-2028 (USD Million)

FIGURE 25 Europe gastric cancer diagnostics market: By age group, CAGR (2021-2028)

FIGURE 26 Europe gastric cancer diagnostics market: By age group, LIFELINE CURVE

FIGURE 27 Europe gastric cancer diagnostics market: By disease type, 2020

FIGURE 28 Europe gastric cancer diagnostics market: By disease type, 2021-2028 (USD Million)

FIGURE 29 Europe gastric cancer diagnostics market: By disease type, CAGR (2021-2028)

FIGURE 30 Europe gastric cancer diagnostics market: By disease type, LIFELINE CURVE

FIGURE 31 Europe gastric cancer diagnostics market: By stage, 2020

FIGURE 32 Europe gastric cancer diagnostics market: By stage, 2021-2028 (USD Million)

FIGURE 33 Europe gastric cancer diagnostics market: By stage, CAGR (2021-2028)

FIGURE 34 Europe gastric cancer diagnostics market: By stage, LIFELINE CURVE

FIGURE 35 Europe gastric cancer diagnostics market: By gender, 2020

FIGURE 36 Europe gastric cancer diagnostics market: By gender, 2021-2028 (USD Million)

FIGURE 37 Europe gastric cancer diagnostics market: By gender, CAGR (2021-2028)

FIGURE 38 Europe gastric cancer diagnostics market: By gender, LIFELINE CURVE

FIGURE 39 Europe gastric cancer diagnostics market: By sample type, 2020

FIGURE 40 Europe gastric cancer diagnostics market: By sample type, 2021-2028 (USD Million)

FIGURE 41 Europe gastric cancer diagnostics market: By sample type, CAGR (2021-2028)

FIGURE 42 Europe gastric cancer diagnostics market: By sample type, LIFELINE CURVE

FIGURE 43 Europe gastric cancer diagnostics market: By end user, 2020

FIGURE 44 Europe gastric cancer diagnostics market: By end user, 2021-2028 (USD Million)

FIGURE 45 Europe gastric cancer diagnostics market: By end user, CAGR (2021-2028)

FIGURE 46 Europe gastric cancer diagnostics market: By end user, LIFELINE CURVE

FIGURE 47 Europe gastric cancer diagnostics market: By distribution channel, 2020

FIGURE 48 Europe gastric cancer diagnostics market: By distribution channel, 2021-2028 (USD Million)

FIGURE 49 Europe gastric cancer diagnostics market: By distribution channel, CAGR (2021-2028)

FIGURE 50 Europe gastric cancer diagnostics market: By distribution channel, LIFELINE CURVE

FIGURE 51 EUROPE Gastric Cancer Diagnostics MARKET: SNAPSHOT (2020)

FIGURE 52 EUROPE Gastric Cancer Diagnostics MARKET: BY COUNTRY (2020)

FIGURE 53 EUROPE Gastric Cancer Diagnostics MARKET: BY COUNTRY (2021 & 2028)

FIGURE 54 EUROPE Gastric Cancer Diagnostics MARKET: BY COUNTRY (2020 & 2028)

FIGURE 55 EUROPE Gastric Cancer Diagnostics MARKET: BY PRODUCT TYPE (2021-2028)

FIGURE 56 Europe Gastric Cancer diagnostics Market: company share 2020 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Europe Gastric Cancer Diagnostics Market is projected to grow at a CAGR of 8.1% during the forecast period by 2030.
The future market value of the Europe Gastric Cancer Diagnostics Market is expected to reach USD 428.98 million by 2030.
The major players in the Europe Gastric Cancer Diagnostics Market are BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., etc.
The countries covered in the Europe Gastric Cancer Diagnostics Market are Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, rest of Europe.

관련 페이지 탐색

Banner